• 제목/요약/키워드: Cardiovascular drug

검색결과 355건 처리시간 0.029초

중증 근무력증환자에서 흉선절제술의 효과 및 임상적 고찰 (A Clinical Analysis of Surgically Treated Myasthenia Gravid)

  • 민경석;조유원
    • Journal of Chest Surgery
    • /
    • 제29권1호
    • /
    • pp.73-78
    • /
    • 1996
  • 1989년 6월부터 1994년 5월까지 5년 동안 임상적으로 중증근무력증으로 진단받고 흉선절제술을 시행받은 23례를 대상으로 하였고, 흉선절제술의 효과를 평가하기 위하여 연령 및 성별분포, 수술전 증상의 정도와 유병 기간, 수술후 호전정도 그리고 총선의 병리 소견과 별기에 따른 흉선절제술의 결과를 분석하였다. 수술후 추적기간은 5개월에서 60개월로 평균 15개월이었다. 흉선절제술의 효과를 환자의 수술후 임상증상의 호전정도와 수술후 약물용량으로 분류하여 본 바 a) 완전회복이 5례 (21.7%), b) 임상증상의 현저 한 호전및 얕용량 감소가 11례 (47.8%), c) 약용량은 같으나 임상증상의 현저한 호전이 3례 (13.0%), 4)호전없음이 2례 (8.7%), e)사망이 1례(4.3%), f) 재발이 1례 (4.3%)로서 23례 중 19례 (82.5%)에서 완전회복 및 임상증상의 현저한 호전을 보였다. 수술전 증상의 중증도와 흉선절제술의 효과를 분석한바, Modified Osserman Staging 분류상 제1군 9례중 6례 (66.7%)가 임상적 호전을 보였고, 3례 (33.3%)에서는 호전이 없었다. 흉선절제술의 효과가 이 두 Group (제I기, 제II기)간에서 유의한 차이는 없었다(P>0.05). 수술후 흉선의 병리 \ulcorner흉선절제술의 효과를 분석한바, 정상흉선의 4례는 전례 (100%)에서 모두 호전을 보였고, 과형 성 11례 에서는 10례 (90.9%)에서 호전을, 1례 (9.1%)에서는 변화가 없었다. 총선종이 있었던 8례 에서는 5례 (62.5%)에서 임상적 호전을 보인 반면 3례 (37.5%)에서는 변화가 없었다. 흉선조직의 병리에 따른 흉선절제술의 효과와의 유의한 차이는 보이지 않았다(P>0.05). 흉선절제술을 시행받은 대부분의 환자(82.5%)에서 완전회복 및 임상증상의 현저한 호전을 가져 왔다. 그러나 수술전 예후에 영향을 미치는 인자로 알려진 증상의 중증도나, 흉선의 병리소견과 수술후 근무력증 치료효과간에 통계적 유의성은 없었다(P>0.05).

  • PDF

${\beta}_1/{\beta}_2$ 비선택적 Radioligand $(-)-[^3H]-DHA$를 사용한 Rat 좌심실 ${\beta}-adrenoceptor$에 대한 심장순환계 약물의 Binding (Binding Studies of Cardiovascular Drug on ${\beta}$ Adrenoceptors in Rat Left Ventricle using $(-)-[^3H]-DHA$, $Non-{\beta}_1/{\beta}_2-selective$ Radioligand)

  • 권광일;이선경;유성은
    • 대한약리학회지
    • /
    • 제27권2호
    • /
    • pp.119-123
    • /
    • 1991
  • ${\beta}-$수용체 효능약물 ((-)-NE), 길항약물 $((\pm)-propranolol,\;labetalol)$ 및 PDE 억제약물(imazodan, KR-30045, KR-30075 등)에 대한 ${\beta}-adrenoceptor$ binding 실험을 ${\beta}_1/{\beta}_2$ 비선택적 radioligand인 $(-)-[^3H]-DHA$를 사용하여 실시하였다. Saturation 실험에서 ${\beta}_1$${\beta}_2$ 수용체를 모두 갖고 있는 rat 좌심실의 ${\beta}$ 수용체에 대한 $(-)-[^3H]-DHA$$K_d$ 값은 $1.5{\pm}0.43\;nM$, $B_{max}$$22.0{\pm}0.9\;fmol/mg$ protein이었다. $({\pm})propranolol$, labetalol 및 (-)NE는 단일상으로 $(-)-[^3H]-DHA$의 결합을 억제하였으며 Ki 값은 각각 $17.0{\pm}0.43\;nM$, $57.3{\pm}1.30\;nM$, $1.57{\pm}0.95\;{\mu}M$로 나타났다. 실험에 사용한 모든 PDE 억제약물들은 $(-)-[^3H]-DHA$ 결합을 $10^{-3}\;M$의 고농도에서도 10% 미만으로 억제했다. 실험결과, propraolol, labetalol 및 NE는 ${\beta}_1/{\beta}_2$ 수용체에 대해 비선택적인 약물로 나타났으며, imazodan 및 신합성 PDE 억제약물들은 rat 심근에 있는 ${\beta}-$수용체에 친화성이 거의 없음을 알 수 있었다.

  • PDF

시간경과에 따른 지연성근통증 내측 비복근의 초음파 영상 (Medial Gastrocnemius Ultrasound Imaging of Delayed Onset Muscle Soreness over time)

  • 이완희;조기훈;이경숙;김미화
    • 한국산학기술학회논문지
    • /
    • 제13권6호
    • /
    • pp.2632-2640
    • /
    • 2012
  • 본 연구의 목적은 지연성근통증에 대한 내측 비복근 초음파 영상의 측정도구로서의 가능성에 대해 알아보고자 함에 있다. 본 연구는 2011년 4월 21일부터 4월30일까지 실시되었다. 평소 규칙적인 운동을 하지 않으며, 최근 외상의 경험, 근골격계 질환, 심혈관계 질환이 없고 약물을 복용하지 않는 35명의 건강한 성인이 참여하였다. 대상자들은 5시간의 등반을 통해 지연성근통증을 유발하였으며, 지연성근통증 전과 지연성근통증 후 24, 48, 72시에 통증(visual analogue scale :VAS), 혈중 크레아틴 키나아제(creatine kinase: CK) 활성도, 족저 굴곡근의 최대근수축력(maximal voluntary isometric contraction: MVlC)을 측정하였고, 이 측정값과 초음파로 측정한 내측 비복근의 우상각을 비교하였다. 연구의 결과는 다음과 같다. 통증지표, 혈중 크레아틴 키나아제 활성도, 족저 굴곡근 최대등척성근수축력에 측정시기에 따른 유의한 차이가 발생하였으며(p<0.05), 내측 비복근 우상각에서도 측정시기에 따른 유의한 차이가 발생하였다(p<0.05). 또한 변수 간 측정시기에 따른 변화의 흐름이 일치하는 것을 확인하였다. 본 연구를 통해 초음파 검사를 통한 내측 비복근 우상각의 시간경과에 따른 변화 측정이 지연성근통증을 감지하는 새로운 측정방법으로 사용될 수 있을 것이라 생각한다.

Effect of Dietary Chlorella Complex on Anticancer Activity in Mice

  • Jung Jae-Hak;Jin Kyong-Suk;Kim Yong-Ho;Lee Yong-Woo
    • 대한의생명과학회지
    • /
    • 제11권2호
    • /
    • pp.185-192
    • /
    • 2005
  • Dietary chlarella has known as one of the best candidates for development of multifunctional probiotic foods owing to an excellent nutritional value such as high amount of proteins and various, valuable fatty acids. So many efforts were devoted to studying the chlorella as therapeutic agents or foods fighting against many diseases in the aged people such as cardiovascular diseases and cancers. In this study, we investigated sizes and weights of tumors derived from mice injected subcutaneously with tumorigenic cells to see if antitumor activity would be found in mice dieted with the chlarella complex. After BALB/c mice were dieted with $5\%$ organic cultured chlorella complex diet throughout for 19weeks, the fibrosarcoma was induced by subcutaneous injection of tumorigenic cells at the 3 weeks before sacrifice. The average weight of tumors in the diet group were significantly reduced to $60\%\;(P=0.012)$ of the one in control group, indicating that diet with the chlarella complex may have anticancer activity in mice. When the mice were dieted with $5\%$ organic cultured chlorella complex for 4 weeks before injecting the tumorigenic cells in order to see tumor-preventive effect of the diet, the potential preventive activity of the diet against cancer was implicated by the observation that the tumors were greatly reduced in the diet group to $37\%$ (P=0.l44) of the control group. Especially, when the $5\%$ diet were applied to mice after injecting with the tumorigenic cells, the tumors derived from the $5\%$ diet group were also decreased to $95\%$ (P=0.002) of those in the control group, suggesting that the diet with the organic cultured chlorella complex may also have therapeutic effect against tumor formation. As results, it was shown that the chlorella complex tested in this study had preventive and therapeutic effects on fighting against tumorigenesis. Therefore, the identification and further mechanistic study of the components which may be associated with antitumor activity from diet of the chlorella complex in the future will contribute to the development of anticancer probiotic foods, alternative therapeutic treatment against cancer, and a new anticancer drug.

  • PDF

방풍통성산이 비만인에 미치는 영향에 대한 임상적 연구 (Clinical study of Bangpoongtongsungsan on body weight change in subjects with obesity)

  • 신대희;조국현;이혁;문미경;강대길;윤용갑;박도심;정선관;이호섭
    • 대한한의학방제학회지
    • /
    • 제16권2호
    • /
    • pp.133-144
    • /
    • 2008
  • Recently, people are becoming fatter in most parts of the world. Obesity is regarded as an important risk factor to adversely affect the health of humans, associated with hypertension, hyperlipidemia, diabetes, and cardiovascular diseases. In the present study, therefore, we tested the short time efficiency and safety of Bangpoongtongsungsan as a drug to decrease body weight in subjects with obesity. A total 48 volunteers (24 man, 24 woman) with body mass index (BMI : weight in kg divided by square of height in meters) of $23㎏/m^2$ participated in clinical study for 12 weeks, from 2008, March 01 to 2008, Jun 30. The subjects was received a dietary supplement of 12 pieces hard capsules per day (4 pieces in one, 3 times in a day) during the clinical study. At the end of clinical study, body weight of subjects was significantly decreased from $72.21{\pm}11.44\;kg$ to $70.53{\pm}11.67\;kg$ (p<0.05). Waist circumferences of subjects were reduced $91.58{\pm}6.43\;cm$ to $85.25{\pm}7.70\;cm$ (p<0.05). Also, a BMI of subjects was significantly decreased $26.07{\pm}2.35\;kg/m^2$ to $25.63{\pm}2.63\;kg/m^2$ (p<0.05). Particularly, a decrease in body weight, waist circumferences, and BMI was more significant in woman than man. But, other biochemical levels including lipid and glucose in plasma had no changes at the end of clinical study. In conclusion, administration of Bangpoongtongsungsan in subjects with high body weight fat could inhibit obesity associated with a decrease in body weight, waist circumferences, and BMI.

  • PDF

Comparative Drug Evaluation of Atorvastatin versus Rosuvastatin in Pharmacotherapy of Korean Patients with Dyslipidemia

  • Park, Seon-Young;Lee, Myung-Koo;Lim, Sung-Cil
    • Biomolecules & Therapeutics
    • /
    • 제16권1호
    • /
    • pp.54-60
    • /
    • 2008
  • Dyslipidemia is the multiple lipid metabolic disorders which is one of the high risk factors for the atherosclerotic diseases. It increases the morbidity and mortality and therefore, must be treated with antilipidemic agents. HMG-Co A reductase inhibitors (statins), one of many antidyslipidemic agents, have shown to be significant improvement from the various cholesterol levels. Especially, data from many comparative trials suggest that rosuvastatin is more effective than atorvastatin among many other statins. The aims of this study were to evaluate the efficacy and safety between rosuvastatin and atorvastatin in the treatment of Korean patients with dyslipidemia. Currently the Korean Society of Lipidology and Atherosclerosis based on the Korean health screening data suggests that Korean patients with dyslipidemia should be treated by the target cholesterol levels according to the Adult Treatment Panel III guidelines of the US National Cholesterol Education Program (NCEP-ATP III). We reviewed retrospectively all medical histories of the total 392 dyslipidemic patients with atorvastatin or rosuvastatin from June 1st, 2004 to August 31st, 2006 in Chungbuk National University Medical Center. Patients were classified as total 4 groups by the NCEP-ATP III Guidelines. The numbers of enrolled patients were each 5 mg atorvastatin (n=34), 10 mg atorvastatin (n=148), 5 mg rosuvastatin (n=94) and 10 mg rosuvastatin (n=82). In comparison between groups, rosuvastatin groups in the lowering LDL-C had better efficacies, and the results were each 22% (5 mg atorvastatin), 33.3% (10 mg atorvastatin), 35% (5 mg rosuvastatin) and 41.3% (10 mg rosuvastatin) with the dose relationship (P=0.000). Rosuvastatin groups also have shown to be more significantly reducing Total Cholesterol levels compared to atorvastatin groups with the no dose relationship (P=0.000). In the lowering of non-HDL cholesteroles, rosuvastatin groups showed significantly better efficacies than atorvastatin with the dose-relationship (P=0.000). Each medication groups did not demonstrate the differences in the changing of HDL cholesterol and triglyceride levels (P=0.096, 0.309, respectively). In conclusion, rosuvastatin was better efficacious than atrovastatin in reducing LDL-C Total Chol, and Tg. Therefore, rosuvastatin is a good antilipidemic agents for Korean patients with dyslipidemia and it can use to minimize the morbidity and mortality related to the cardiovascular diseases in Korean.

N2 종격동 림프절 전이가 있는 제 III A 병기 비소세포폐암에 있어 수술전 동시화학방사선요법 후 폐적출술의 조기 성적 (Early Result of Surgical Resection after Pre-Operative Concurrent chemoradiotherapy for N2-Positive Stage IIIA NSCLC)

  • 차대원;김진국;심영목;김관민;박근칠;안용찬
    • Journal of Chest Surgery
    • /
    • 제33권8호
    • /
    • pp.662-668
    • /
    • 2000
  • Background: Many recent results of clinical trials show that pre-operative concurrent chemoradiotherapy and surgical resection could increase the survival of N2 positive stage IIIA non-small cell lung cancer. This study was performed to assess the feasibility, toxicity, and affect rates of concurrent chemoradiotherapy and surgical resection in N2 positive stage IIIA non-small cell lung cancer. Material and Method: Thirty-one patients who underwent preoperative concurrent chemoradiotherapy for N2 positive stage IIIA non-small-cell lung cancer from May 1997 to April 1999 were entered into the study. Mean age was 61 yrs(43∼70 yrs), There were 24 men and 7 women. The confirmation of N2 disease were achieved through mediastinoscopic biopsy(24) and CT scans(7). Induction was achieved by two cycles of cisplatin and etoposide(EP) plus concurrent chest radiotherapy to 45 Gy. Resections were done at 3 weeks after the complection of preoperative concurrent chemoradiotherapy. Resections were performed in 23 patients, excluding 5 refusals and 3 distant metastasis. Result: All patients were compled the thoracic radiotherapy except one who had distant metastasis. Twenty three patients were completed the planned 2 cycles of EP chemotherapy, and 8 patients were received only 1 cycle for severe side effects(6), refusal(1), and distant metastasis(1). There was one postoperative mortality, and the cause of death was ARDS. Three patients who had neutropenic fever and one patient who had radiation pneumonitis were required admission and treatment. Esophagitis was the most common acute side effect, but relatively well-tolerated in most patients. The complection rate of concurrent chemoradiotherapy was 74%, resection rate was 71%, pathologic complete remission rate was 13.6%, and pathologic down-staging rate was 68%. Conclusion: Morbidity related to each treatment was acceptable and many of the patients have benefited down staging of its disease. Further prospective, preferably randomized, clinical trials of larger scale may be warranted to confirm the actual benefit of preoperative concurrent chemoradiotherapy and surgical resection in N2-positive stage IIIA non-small cell lung cancer.

  • PDF

우중하엽 폐허탈 및 폐쇄세기관지기질화 폐렴을 유발한 기관지 지방종 1예 (A Case of Endobronchial Lipoma Causing Right Middle and Lower Lobes Collapse and Bronchiolitis Obliterans-organizing Pneumonia)

  • 손지영;정지예;하유정;홍수정;정민규;정문재;서용성;문지애;변민광;박병훈;문진욱;박무석;김영삼;장준;김상겸;정경영;김세규
    • Tuberculosis and Respiratory Diseases
    • /
    • 제65권4호
    • /
    • pp.313-317
    • /
    • 2008
  • 저자들은 기침, 우측 흉부 불쾌감을 주소로 내원한 58세 남자 환자에서 기관지내시경 육안 소견상 양성 종양이 의심 되었으나 조직 검사상 지방종을 확진하지 못하였고 악성 종양을 배제할 수 없는 상황에서 종괴에 의한 우중엽과 우하엽의 허탈 및 폐쇄성 폐렴 때문에 수술적 치료를 시행하였으며, 수술 결과 기관지 지방종에 의한 폐허탈과 함께 폐쇄세기관지기질화 폐렴이 발생한 예가 있어 보고하는 바이다.

입원환자 낙상 발생 실태와 원인에 관한 분석 연구 (An Analysis of Fall Incidence Rate and Its Related Factors of Fall in Inpatients)

  • 김철규;서문자
    • 한국의료질향상학회지
    • /
    • 제9권2호
    • /
    • pp.210-228
    • /
    • 2002
  • Background: The purpose of this research was to examine the fall incidence rate and its related factors of fall in inpatients. Methods: The data were collected from the 138 fall incident reports in one tertiary hospital in Seoul from April 1st 1999 to September 30th 2001. The Fall Incident Report Form was originally developed based on that of Massachusetts General Hospital revised in 1995. And this was modified for this survey by the collaborating work of QI team including researcher and department of nursing service of this particular hospital. The contents of Fall Incident Form were general characteristics of patient. factors related to fall. types and places of fall. circumstances, nursing interventions. and outcome. Results: 1) The incidence rate of fall was 0.08% of total discharged patients and 0.081 per 1000 patient-day. This incidence rate is much lower than that of several hospitals in USA. This finding might result from the different incidence report system of each hospital. 2) The characteristics of fall-prone patient were found as follows. They were mostly over 60 years old, in alert mental status, ambulatory with some assistance, and dependent on ambulatory device. The types of diseases related high incidence rate were cerebrovascular disease(3.2), hypertension(1.6), cardiovascular disease(1.4), diabetes(1.3) and liver disease(0.6). 3) The majority of fall events usually occurred m bed. bedside(walking or standing) and bathroom in patient room. Usually they were up on their own when they fell. And there were more falls of elderly occurred during night time than day or evening. 4) 63.8% of fall events resulted in physical injuries such as fracture and usually the patients had diagnostic procedures and some treatment(ex. suture) which caused additional cost to the patients and their families. 5) The found risk factors of fall were drugs(antihypertensive drug, diuretics) and environmental factors like too high bed height, long distance of bedside table and lamp switch, and slippery tile of bathroom floor. Conclusion: Considering these results, every medical and nursing staff should be aware of the risk factors of patients in hospital, and should intervene more actively the preventive managements, specially for the elderly patients during night. Therefore, it is recommended that the development of Fall Prevention Programs based on these results.

  • PDF

Latex of Ficus carica L. Induces Apoptosis Through Caspase and Bcl-2 Family in FaDu Human Hypopharynx Squamous Carcinoma Cells

  • Shin, Bo Su;Lee, Seul Ah;Moon, Sung Min;Han, Seul Hee;Hwang, Eun Ju;Kim, Su-Gwan;Kim, Do Kyung;Kim, Jin-Soo;Park, Bo-Ram;Kim, Chun Sung
    • International Journal of Oral Biology
    • /
    • 제42권4호
    • /
    • pp.183-190
    • /
    • 2017
  • Ficus carica L. (common fig), one of the first plants cultivated by humans, originated in the Mediterranean basin and currently grows worldwide, including southwest Asia and South Korea. It has been used as a traditional medicine for treatment of metabolic, cardiovascular, and respiratory diseases as well as hemorrhoids and skin infections. Its pharmacological properties have recently been studied in detail, but research on the anti-cancer effect of its latex has been only been studied on a limited basis on several cell lines, such prostate cancer, breast cancer, and leukemia. In this study, we investigated the anti-cancer activity of the latex of Ficus carica L.and its underlying mechanism in FaDu human hypopharynx squamous carcinoma cells. (See Ed. note above) We confirmed through SDS-PAGE analysis and gelatinolytic activity analysis that the latex of Ficus carica contains cysteine protease ficin. Our data showed that the latex inhibited cell growth in a dose-dependent manner. In addition, the latex treatment markedly induced apoptosis in FaDu cells as determined by FACS analysis, elevated expression level of cleaved caspase-9, -3 and PARP (poly (ADP-ribose) polymerase), and. increased the expression of Bax (pro-apoptotic factor) while decreasing the expression of Bcl-2 (anti-apoptotic factor). Taken together, these results suggested that latex containing the ficin inhibited cell growth and induced apoptosis by caspase and the Bcl-2 family signaling pathway in FaDu human hypopharynx squamous carcinoma cells. These findings point to the potential of latex of Ficus carica to provide a novel chemotherapeutic drug due to its growth inhibition effects and induction of apoptosis in human oral cancer cells.